" class="no-js "lang="en-US"> TargEDys and SymbioPharm Enter an Exclusive Partnership to launch SymbioLife® Satylia® in Germany - Medtech Alert
Sunday, May 19, 2024

TargEDys and SymbioPharm Enter an Exclusive Partnership to launch SymbioLife® Satylia® in Germany

TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® in Germany. The novel dietary supplement based on the next-generation probiotic Hafnia alvei HA4597 will be available from January 2023.

SymbioLife® Satylia® is a precision probiotic with a characterized mechanism of action at molecular level: it increases satiety thanks to the protein ClpB produced by Hafnia alvei HA4597. ClpB naturally mimics the human satiety hormone alpha-MSH. The improved feeling of satiety helps with successful weight loss, as confirmed by a clinical study with 230 overweight adults. This natural principle provided by SymbioLife® Satylia® is a multi-awarded new, natural, safe and effective weight management solution.

Grégory Lambert, CEO of TargEDys, “We are extremely proud and excited about this new collaboration. SymbioPharm is in the top 3 of the German probiotics market and fathered one of the first probiotic pharmaceuticals globally. With the team’s knowledge of probiotic Enterobacteria, their strong position with doctors, pharmacies, and synergies with probiotics and diagnostics, they are the perfect partner for this highly scientific product.”

Juergen Eck, Co-CEO and CTO of SymbioPharm, “We are very excited to partner with TargEDys and work together on a new era of evidence-based probiotics. With the patent-protected probiotic Hafnia alvei HA4597, its biological mechanism of action and outstanding studies, we can offer an effective solution for the growing problems of obesity and metabolic health. As pioneers in microbiome research and medical probiotics, we are proud to now also help shape the introduction of knowledge-based precision probiotics.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more